June 2021

Presentations

Brentuximab Vedotin | Diffuse Large B-cell Lymphoma | Abstract TPS7571

Brentuximab Vedotin in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Trial in Progress)

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract 7528

Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYAs) With Stage III or IV Hodgkin Lymphoma: a Subgroup Analysis From the Phase 3 ECHELON-1 Study

Tucatinib | Breast Cancer | Abstract 1043

Updated Results of Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients With Pretreated HER2+ Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB)

Tucatinib | Solid Tumors | Abstract TPS3151

SGNTUC-019: Phase 2 Basket Study of Tucatinib and Trastuzumab in Previously Treated Solid Tumors with HER2 Alterations (Trial in Progress)

Tucatinib | Breast Cancer | Abstract TPS1097

HER2CLIMB-04: Phase 2 Open Label Trial of Tucatinib + Trastuzumab Deruxtecan in Patients With HER2+ Unresectable Locally-Advanced or Metastatic Breast Cancer With and Without Brain Metastases (Trial in Progress)

Tisotumab Vedotin | Cervical Cancer | Abstract TPS5596

Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer (innovaTV 301/ENGOT cx12/GOG 3057, Trial in Progress)

SGN-B6A | Solid Tumors | Abstract TPS3144

A Phase 1 Study of SGN-B6A, an Antibody-Drug Conjugate Targeting Integrin Beta-6, in Patients With Advanced Solid Tumors (SGNB6A-001, Trial in Progress)

SEA-TGT | Advanced Malignancies | Abstract TPS2657

SGNTGT-001: A Phase 1 Study of SEATGT, an Effector-Function Enhanced Monoclonal Antibody (mAb), in Advanced Malignancies (Trial in Progress)

Enfortumab Vedotin | Urothelial Carcinoma | Abstract 4528

Study EV-103: Update on Durability Results and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in First Line Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

Enfortumab Vedotin | Urothelial Cancer | Abstract 4524

Enfortumab Vedotin in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer Who Received Prior PD-1/PD-L1 Inhibitors: An Updated Analysis of EV-201 Cohort 2

Enfortumab Vedotin | Urothelial Carcinoma | Abstract 4539

Quality of Life, Functioning, and Symptoms in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma From EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy

Enfortumab Vedotin | Bladder Cancer | Abstract TPS4587

KEYNOTE-B15/EV-304: Randomized Phase 3 Study of Perioperative Enfortumab Vedotin Plus Pembrolizumab Versus Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC)